Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
HER-2/neu overexpression decreases wild-type p53 via activating PI3K pathway
March 31st, 2005
HER-2/neu overexpression decreases wild-type p53 via activating PI3K pathway. According to a study from Fudan University, Shanghai, China, "Overexpression and activation of HER-2/neu (also known as c-erbB-2), a proto-oncogene, was found in about 30% of human breast cancers, promoting cancer growth and making cancer cells resistant to chemo- and radio-therapy. "Wild-type p53 is crucial in regulating cell growth and apoptosis and is found to be mutated or deleted in 60-70% of human cancers. And some cancers with a wild-type p53 do not have normal p53 function, suggesting that it is implicated in a complex process regulated by many factors." ...
Source: Women's Health Weekly (2005-03-31)
|
